Health services need to plan around a growing number of people taking weight-loss injections such as Wegovy for life, not just two years. The sooner they face up to that, the better, says ClareWilsonMed.
HEALTHCARE systems around the world are grappling with the arrival of a new kind of weight-loss treatment:The UK is among the first countries where semaglutide looks set to be made available for weight-loss treatment through a publicly funded health system.
Unfortunately, many doctors think England’s guidance body has made a misstep by recommending people be restricted to two years of use, even though the drug is meant to be taken long-term. Health systems in other countries are also debating how to respond to this unprecedented situation, …
México Últimas Noticias, México Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
Psychiatrists Prescribe Wegovy for Medication-Induced Weight GainPsychiatrists are increasingly prescribing the popular weight-loss drug Wegovy to patients who gain weight from medicines used to treat mental disorders, such as schizophrenia or bipolar disorder.
Leer más »
Novo's weight-loss drug Wegovy cuts risk of heart disease by 20% - trial dataNovo Nordisk's obesity drug Wegovy has shown a clear medical benefit, reducing the risk of heart disease by 20% according to a large late-stage study. The positive results have boosted the Danish drugmaker's hopes of repositioning Wegovy as more than just a lifestyle drug.
Leer más »
Weight-Loss Drug Wegovy Cuts Heart Attack, Stroke Risk by 20% in New StudyAnti-obesity drug Wegovy not only helped people lose weight but also reduced their risk of suffering heart attacks, strokes and cardiovascular deaths by 20% in a study
Leer más »
Novo weight-loss drug Wegovy shows heart benefit in trialNovo Nordisk announced that a trial has revealed that patients taking the weight-loss drug Wegovy had a 20% lower risk of heart attack, stroke, or death from heart disease compared to those on a placebo. This finding gives hope to Novo Nordisk in expanding the perception of Wegovy beyond being just a lifestyle drug.
Leer más »
Study: Weight-loss drug Wegovy cuts heart attack risk in those with obesityA recent study has found that the weight-loss drug Wegovy can significantly reduce the risk of heart attacks in individuals with obesity. This discovery could lead to an increased demand for the drug and strengthen the argument for insurance coverage. Experts emphasize that obesity should be treated as a serious illness due to its association with various health issues, including heart disease. However, private insurers have been hesitant to cover Wegovy, and Medicare is currently prohibited from covering weight-loss medications.
Leer más »
Novo's Wegovy Shows Heart Benefit Alongside Weight Loss in TrialNovo Nordisk, the maker of Wegovy, announced that a large study has demonstrated the cardiovascular benefits of the highly effective obesity treatment. This finding is significant as it allows the Danish company to expand its market beyond being perceived as a lifestyle drug. The positive results from the trial may also encourage insurers in the U.S. and cost-conscious health authorities in Europe to cover the cost of Wegovy for a wider range of patients.
Leer más »